Shots:
- Merck has entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346
- As per the deal, Merck has obtained exclusive rights to develop, manufacture & commercialize HRS-5346 globally excl. Greater China region in exchange for $200M upfront & ~$1.77B in development, regulatory & commercial milestones, along with net sales-based royalties; closing expected in Q2’25
- HRS-5346 is an oral, small molecule lipoprotein(a) inhibitor that is being investigated in a P-II trial in China for cardio-metabolic diseases
Ref: Merck | Image: Merck & Jiangsu Hengrui
Related News:- Merck Reports P-III (MK-8591A-052 & MK-8591A-051) Trial Data of Doravirine + Islatravir (DOR/ISL) for HIV-1 Infection in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
